5



I claim:

- 1. A prodrug for use in the treatment of physiological conditions comprising a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl, wherein the carrier moiety is chemically linked to a therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally.
 - 2. The prodrug of claim 1, wherein n is an integer from 3 to 6.
 - 3. The prodrug of claim1, wherein n is $\underline{5}$.
- 4. The prodrug of claim 1, wherein the polypeptide is Tyr-Gly-Gly-Phe-Met.
- 5. The prodrug of claim 1, wherein the prodrug further comprises a non-therapeutic linker species linking the polypeptide to the carrier species.
- 6. The prodrug of claim 5, wherein the linker species is an amino acid.
- 7. A pharmaceutical composition comprising a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4 methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl chemically linked to a

5






therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, wherein the polypeptide is poorly absorbed orally, and a pharmaceutically of effective adjuvant species.

- 8. A method for enhancing the oral availability of therapeutic polypeptides of the general formula formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, wherein the method comprises the step of chemically linking the polypeptide to a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4 methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl to form a prodrug.
- 9. The method of claim 8, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 10. The method of claim 9, wherein the linker species is an amino acid.
- 11. A method for the treatment of a physiological condition through the oral administration of a therapeutically effective species comprising the steps of:
 - a.) chemically linking a therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, to a carrier moiety selected from the group comprising cinnamoyl, benzoyl,

5

10



- b.) orally administering the prodrug to a patient exhibiting the physiological condition.
- 12. The method of claim 11, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 13. The method of claim 12, wherein the linker species is an amino acid.
- therapeutically effective polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, comprising the steps of:
 - a.) chemically linking the polypeptide to a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl to form a prodrug; and
 - b.) orally administering the prodrug to a patient.
- 15. The method of claim 14, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 16. The method of claim 15, wherein the linker species is an amino acid.

odd /

10

5